Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.35 |
| ▸ | AR | P10275 | 6/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD5 | P21918 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 3/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5856488 | 0.91 | AR (0.33) | ARPPARAITGB3ITGA2BPPARG | |
| SCHEMBL5854668 | 0.88 | ESR1 (0.39) | ESR1ARGRIN2BDRD2DRD1 | |
| SCHEMBL5854600 | 0.88 | ESR1 (0.44) | ESR1GRIN2B | |
| SCHEMBL5855053 | 0.86 | GRIN2B (0.34) | ESR1GRIN2B | |
| SCHEMBL5855464 | 0.86 | ESR1 (0.45) | ESR1GRIN2BESR2 | |
| SCHEMBL6801409 | 0.85 | ESR1 (0.33) | ESR1GRIN2B | |
| SCHEMBL5857202 | 0.85 | ESR1 (0.33) | ESR1GRIN2B | |
| SCHEMBL5857545 | 0.84 | ESR1 (0.34) | ESR1GRIN2BESR2 | |
| SCHEMBL5854186 | 0.83 | ESR1 (0.34) | ESR1GRIN2B | |
| SCHEMBL5854452 | 0.83 | ESR1 (0.34) | ESR1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074819-B2 | Benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2004-05-27 | — | — | US | disclosed |
| US-6645951-B1 | Antiestrogens for treating breast cancer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | NR5A1, SHBG, ESR2 | ESR1 12/4885AR 23/4885GRIN2B 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.